Literature DB >> 3875666

Alteration of the cell wall of Haemophilus influenzae type b by transformation with cloned DNA: association with attenuated virulence.

A Zwahlen, L G Rubin, C J Connelly, T J Inzana, E R Moxon.   

Abstract

A virulent strain of Haemophilus influenzae type b was used to construct a lambda library of chromosomal DNA in Charon 4, amplified in Escherichia coli. From this library a recombinant (I-69) phage was isolated that contained a 10.2-kilobase-pair fragment of DNA eliciting H. influenzae transformants whose colonies had a distinctive opaque phenotype. Compared with their H. influenzae parent strains the opaque I-69 transformants had two defined cell wall alterations: one in the lipopolysaccharide (greater mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and one in the outer membrane proteins. The I-69 transformant of virulent type b strain Rd-/b+ had stable expression of type b capsule. In contrast to strain Rd-/b+, the Rd-/b+/I-69 transformant was serum sensitive in vitro and avirulent in vivo in rats. Thus the potential of H. influenzae type b organisms to cause invasive infection can be substantially attenuated by altering the expression of one or more genes that affect the cell wall composition.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875666     DOI: 10.1093/infdis/152.3.485

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

Review 1.  Challenge of investigating biologically relevant functions of virulence factors in bacterial pathogens.

Authors:  R Moxon; C Tang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

Review 2.  Functional genomics of pathogenic bacteria.

Authors:  E R Moxon; D W Hood; N J Saunders; E K H Schweda; J C Richards
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-01-29       Impact factor: 6.237

3.  Molecular cloning of the Haemophilus influenzae gmhA (lpcA) gene encoding a phosphoheptose isomerase required for lipooligosaccharide biosynthesis.

Authors:  J S Brooke; M A Valvano
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

4.  Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b.

Authors:  P A Gulig; C C Patrick; L Hermanstorfer; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

5.  Phase-variable lipopolysaccharide structures enhance the invasive capacity of Haemophilus influenzae.

Authors:  J N Weiser; A Williams; E R Moxon
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Biosynthesis pathway of ADP-L-glycero-beta-D-manno-heptose in Escherichia coli.

Authors:  Bernd Kneidinger; Cristina Marolda; Michael Graninger; Alla Zamyatina; Fiona McArthur; Paul Kosma; Miguel A Valvano; Paul Messner
Journal:  J Bacteriol       Date:  2002-01       Impact factor: 3.490

7.  Identification of a new locus involved in expression of Haemophilus influenzae type b lipooligosaccharide.

Authors:  G P Jarosik; E J Hansen
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

8.  Involvement of the Haemophilus ducreyi gmhA gene product in lipooligosaccharide expression and virulence.

Authors:  B A Bauer; M K Stevens; E J Hansen
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  OpsX from Haemophilus influenzae represents a novel type of heptosyltransferase I in lipopolysaccharide biosynthesis.

Authors:  Sabine Gronow; Werner Brabetz; Buko Lindner; Helmut Brade
Journal:  J Bacteriol       Date:  2005-09       Impact factor: 3.490

10.  The tetrasaccharide L-alpha-D-heptose1-->2-L-alpha-D-heptose1--> 3-L-alpha-D-heptose1-->(3-deoxy-D-manno-octulosonic acid) and phosphate in lipid A define the conserved epitope in Haemophilus lipopolysaccharides recognized by a monoclonal antibody.

Authors:  S Borrelli; O Hegedus; D H Shaw; P E Jansson; A A Lindberg
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.